TY - JOUR
T1 - No drug-drug interaction between tezacaftor-ivacaftor and clofazimine
T2 - A case report.
AU - Vonk, S. E. M.
AU - Terheggen-Lagro, S. W. J.
AU - Amsterdam Mucociliary Clearance Disease (AMCD) research group
AU - Mouissie, L. M.
AU - Mathôt, R. A. A.
AU - Kemper, E. M.
N1 - Funding Information: We would like to thank the patient for her approval to share her clinical data and contribution to this case report. Publisher Copyright: © 2021
PY - 2022/1/21
Y1 - 2022/1/21
N2 - In this case report the potential drug-drug interaction between cytochrome P450 (CYP) 3A4 substrates tezacaftor-ivacaftor and CYP3A4/5 inhibitor clofazimine is investigated in a patient with cystic fibrosis. Exposure to tezacaftor, ivacaftor and its metabolites was assessed by determination of the area under the plasma concentration versus time curve (AUC0-24 h for tezacaftor and AUC0-12 h for ivacaftor and its metabolite) before start of clofazimine and 8 and 115 days after start of clofazimine. The AUC-ratio at day 115 and pre-start was 1.09, 1.45 and 0.747 for ivacaftor, hydroxymethyl ivacaftor and tezacaftor, respectively. This case suggests that clofazimine exhibits no clinically relevant increase in exposure to tezacaftor and ivacaftor.
AB - In this case report the potential drug-drug interaction between cytochrome P450 (CYP) 3A4 substrates tezacaftor-ivacaftor and CYP3A4/5 inhibitor clofazimine is investigated in a patient with cystic fibrosis. Exposure to tezacaftor, ivacaftor and its metabolites was assessed by determination of the area under the plasma concentration versus time curve (AUC0-24 h for tezacaftor and AUC0-12 h for ivacaftor and its metabolite) before start of clofazimine and 8 and 115 days after start of clofazimine. The AUC-ratio at day 115 and pre-start was 1.09, 1.45 and 0.747 for ivacaftor, hydroxymethyl ivacaftor and tezacaftor, respectively. This case suggests that clofazimine exhibits no clinically relevant increase in exposure to tezacaftor and ivacaftor.
KW - Clofazimine
KW - Drug-drug interaction
KW - Tezacaftor-ivacaftor
UR - http://www.scopus.com/inward/record.url?scp=85119207807&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.jcf.2021.10.003
DO - https://doi.org/10.1016/j.jcf.2021.10.003
M3 - Article
C2 - 34756823
SN - 1569-1993
VL - 21
SP - e5-e7
JO - Journal of cystic fibrosis
JF - Journal of cystic fibrosis
IS - 1
ER -